
-
UroGen Pharma NASDAQ:URGN Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Location: Raanana, 4365007, Israel | Website: www.urogen.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
343.2M
Cash
236.7M
Avg Qtr Burn
-24.19M
Short % of Float
13.68%
Insider Ownership
8.40%
Institutional Own.
87.18%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JELMYTO® (mitomycin) Details Carcinoma , Cancer | Approved Quarterly sales | |
UGN-102 (mitomycin) Details Bladder cancer, Cancer | PDUFA Approval decision | |
UGN-103 Details Bladder cancer, Cancer | Phase 3 Update | |
UGN-104 Details Cancer, Urothelial cancer | Phase 3 Initiation | |
UGN-301 Details Non-muscle invasive bladder cancer | Phase 1 Data readout |